Connect with us

Hi, what are you looking for?


FDA Vaccine Advisors are “Disappointed” and “Upset” that Initial Information Regarding the New Covid-19 Booster Shot wasn’t Given for Study Last Year

Some federal government vaccine consultants claim they are “disappointed” and “angry” that Moderna and government scientists failed to introduce a set of infection data on the company’s brand-new Covid-19 booster during gatherings last year when the consultants discussed if the shot should be approved and made available to the general public.

The information raised the opportunity that the revised booster may not be any more effective than the initial doses at preventing Covid-19 infections.

Several advisers said to CNN that they were worried about a lack of transparency even though the data was initial and had several restrictions.

More than 48.2 million Americans received the new booster, which cost roughly $5 billion in total to manufacture.

Dr. Paul Offit, a member of the Vaccines and Related Biological Products Advisory Committee, a group of outside experts that supports the FDA in making vaccination choices, said, “I was unhappy to find out there was material that was important to our conclusion that we didn’t get to view. “Decisions made for the public must be based on all information available – not just specific information, but all information,” the statement reads.

An overview of the gatherings’ videos, transcripts, and slide presentations by Moderna, CDC, and FDA representatives revealed that the experts were given reams of data proving the new vaccine’s higher performance than the currently available one at both meetings of this FDA advisory group and a committee that instructs the US Centers for Disease Control and Prevention in June and September, respectively.